Hepatobiliary Cancers: Pathobiology and Translational Advances

Ibrutinib in Combination with Sorafenib Synergistically Inhibits Proliferation and Survival of Hepatocellular Carcinoma Cells by Targeting EGFR Signaling Pathway

Cho-Hao Lin, The Ohio State UniversityFollow
Nissar Wani, The Ohio State University
Khadija Elkholy, The Ohio State University
Kalpana Ghoshal, The Ohio State University

Document Type

Abstract Accepted for Presentation

Date

2017

Date of Submission

September 2017

Rights

Is Part Of

Hepatobiliary Cancers: Pathobiology and Translational Advances

Download

Included in

Cancer Biology Commons

COinS

Virginia Commonwealth University is a nationally renowned public research institution dedicated to the success and well-being of all members of its community. VCU student, faculty and staff groups and associations are open without regard to any characteristic or identity protected by law.

Ibrutinib in Combination with Sorafenib Synergistically Inhibits Proliferation and Survival of Hepatocellular Carcinoma Cells by Targeting EGFR Signaling Pathway

Document Type

Date

Date of Submission

Rights

Is Part Of

Included in

Browse

Search

Author Corner

Links

Hepatobiliary Cancers: Pathobiology and Translational Advances

Ibrutinib in Combination with Sorafenib Synergistically Inhibits Proliferation and Survival of Hepatocellular Carcinoma Cells by Targeting EGFR Signaling Pathway

Authors

Document Type

Date

Date of Submission

Rights

Is Part Of

Included in

Share

Browse

Search

Author Corner

Links